Merrill Lynch analyst Jason Gerberry reiterated a Hold rating on Eli Lilly & Co (LLY) yesterday and set a price target of $129. The company’s shares opened today at $128.73, close to its 52-week high of $130.75.
According to TipRanks.com, Gerberry ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.5% and a 38.8% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Cara Therapeutics, and Merck & Company.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $132, implying a 2.5% upside from current levels. In a report released today, Credit Suisse also maintained a Hold rating on the stock with a $121 price target.
See today’s analyst top recommended stocks >>
Based on Eli Lilly & Co’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $1.13 billion. In comparison, last year the company had a GAAP net loss of $1.66 billion.
Based on the recent corporate insider activity of 138 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
